Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease

James D. Doecke, PhD; Simon M. Laws, PhD; Noel G. Faux, PhD; William Wilson, PhD; Samantha C. Burnham, PhD; Chiou-Peng Lam, PhD; Alinda Mondal, MSc; Justin Bedo, PhD; Ashley I. Bush, MD; Belinda Brown, BSc; Karl De Ruzyck, BSc; Kathryn A. Ellis, PhD; Christopher Fowler, BSc; Veer B. Gupta, PhD; Richard Head, PhD; S. Lance Macaulay, PhD; Kelly Pertile, BSc; Christopher C. Rowe, MD; Alan Rembach, PhD; Mark Rodrigues, MSc; Rebecca Rumble, BSc; Cassandra Szoete, MD; Kevin Taddei, BSc; Tania Taddei, BSc; Brett Trounson, BSc; David Ames, MD; Colin L. Masters, MD; Ralph N. Martins, PhD; for the Alzheimer’s Disease Neuroimaging Initiative and Australian Imaging Biomarker and Lifestyle Research Group

Objective: To identify plasma biomarkers for the diagnosis of Alzheimer disease (AD).

Design: Baseline plasma screening of 151 multiplexed analytes combined with targeted biomarker and clinical pathology data.

Setting: General community-based, prospective, longitudinal study of aging.

Participants: A total of 754 healthy individuals serving as controls and 207 participants with AD from the Australian Imaging Biomarker and Lifestyle study (AIBL) cohort with identified biomarkers that were validated in 58 healthy controls and 112 individuals with AD from the Alzheimer Disease Neuroimaging Initiative (ADNI) cohort.

Results: A biomarker panel was identified that included markers significantly increased (cortisol, pancreatic polypeptide, insulinlike growth factor binding protein 2, β; γ-microglobulin, vascular cell adhesion molecule 1, carcinoembryonic antigen, matrix metalloprotein 2, CD40, macrophage inflammatory protein 1α, superoxide dismutase, and homocysteine) and decreased (apolipoprotein E, epidermal growth factor receptor, hemoglobin, calcium, zinc, interleukin 17, and albumin) in AD. Cross-validated accuracy measures from the AIBL cohort reached a mean (SD) of 85% (3.0%) for sensitivity and specificity and 93% (3.0) for the area under the receiver operating characteristic curve. A second validation using the ADNI cohort attained accuracy measures of 80% (3.0%) for sensitivity and specificity and 85% (3.0) for area under the receiver operating characteristic curve.

Conclusions: This study identified a panel of plasma biomarkers that distinguish individuals with AD from cognitively healthy control subjects with high sensitivity and specificity. Cross-validation within the AIBL cohort and further validation within the ADNI cohort provides strong evidence that the identified biomarkers are important for AD diagnosis.


Alzheimer disease (AD) is the most common form of dementia, affecting more than 27 million persons worldwide and predicted to affect 86 million people by the year 2050.1 The disease is characterized morphologically by an overall loss of synapses and neurons and an overall reduction in brain volume.2 The identification of peripheral biomarkers of the disease process leading to an effective and early diagnostic test for AD would allow for presymptomatic detection of disease and would be valuable for monitoring the efficacy of disease interventions during clinical trials.

Currently, cerebrospinal fluid (CSF) has provided the most promising source of validated AD biomarkers. A decline in β-amyloid (Aβ) levels in the CSF has been reported to help distinguish between patients with AD and elderly individuals without AD.3-7 In particular, the longer 42- amino acid isoform Aβ1-42 in combination with levels of the phosphorylated microtubule-associated protein tau (p-tau) has been advocated for use in the diagnosis of AD.8 Perrin and colleagues9 identified other biomarkers, including neuronal cell adhesion molecule, YKL-40 (YKL) represents the first 3 N-terminal amino acids and 40 denotes molecular mass in kilodaltons; also known as human chitin-
ase 3–like 1, cartilage glycoprotein 39, and chondrex), chromogranin A, and carnosinase 1, which improved the diagnostic accuracy of Aβ1-42 and p-tau. Craig-Schapiro and colleagues used a biomarker discovery method from rules-based medicine (RBM) to identify novel CSF biomarkers that distinguish between very mild dementia, mild dementia, and no dementia.

Compared with CSF, blood analysis has advantages as an approach to population-based disease screening because it is simpler and less invasive. As such, there has been strong interest in obtaining usable blood-based biomarkers for AD diagnosis. Ray et al identified a panel of 18 biomarkers from a group of 120 signaling proteins and, more recently, O'Bryant and colleagues used a panel from RBM to identify a list of 30 biomarkers to detect AD. Soares and colleagues describe a list of biomarkers identified within the Alzheimer Disease Neuroimaging Initiative (ADNI) cohort in this issue. Herein, we describe a short articulated panel of blood-based biomarker candidates obtained by comparing clinical factors with blood-based measures from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study, a prospective longitudinal cohort study of aging in Australia. This biomarker panel was then validated in the ADNI cohort. The biomarkers identified in this cross-sectional analysis of data from the AIBL study may contribute toward the development of a blood-based diagnostic test, which together with appropriate imaging phenotypes may deliver an accurate means to diagnose AD.

**METHODS**

**STUDY COHORTS, SAMPLE PREPARATION, AND MULTIPLEX PANEL**

This study refers to initial biomarker screening in 754 healthy individuals serving as controls (HCs) and 207 participants with AD, drawn from the AIBL study. Blood samples were collected from all patients (fasting) on arrival at both Australian sites and were fractionated within 2 hours of collection and snap frozen in liquid nitrogen. Full blood pathology testing (Melbourne Health and PathWest Laboratory Medicine) and apolipoprotein E (APOE; OMIM 107741) genotyping were performed. The APOE genotype discussed within this article relates to testing all possible APOE genotypes.

Plasma (EDTA plus 33 ng/mL prostaglandin E1; Sapphire Biosciences) samples from the AIBL cohort were analyzed with a 151-analyte multiplex panel (Human DiscoveryMAP, version 1.0; RBM). All sample results below the lower limit of quantitation were classed as missing data. Plasma Aβ1-40 and Aβ1-42 peptides were measured using a commercial assay (INNO-BIA plasma Aβ assay; Innogenetics, Inc) and a well-documented double sandwich enzyme-linked immunosorbent technique as described previously. Total APOE and APOE4 protein levels were measured in plasma from fasting participants using a commercial assay (APOE4/Pan APOE ELISA; MBL Co, Ltd), as previously described. Total plasma (lithium heparin) metal iron levels were measured by induction-coupled plasma mass spectrometry. Seven metals were measured: chromium (isotopes 52 and 53; Cr), copper (isotope 65; Cu), iron (isotope 57; Fe), rubidium (isotope 85; Rb), selenium (isotope 78; Se), and zinc (isotope 66; Zn). All available data from a subset of the ADNI study cohort (HC, 58; AD, 112) measured for the RBM protein analyte panel and various clinical pathology measures were used for validation purposes.

**STATISTICAL ANALYSIS**

Demographic and Biomarker Effect Size Comparisons

To compare the basic demographic statistics between the cohorts, χ² analyses (P value from Fisher exact test when necessary) and Mann-Whitney tests were used. A generalized linear model was used, adjusted for age, sex, and APOE genotype, to determine overall biomarker differences between HC and AD individuals. Using the Bonferroni multiple adjustment approach, the α value for P value comparison was .0003 (.05/174). Fold protein change was calculated using unadjusted raw expression values to provide a relative protein difference between HC and AD individuals. The R statistical software environment, version 2.10, was used for all statistical analyses.

Method Overview

A preanalysis stage (eAppendix) was implemented incorporating data cleaning, transformation, and imputation (values available on request from the corresponding author). Subsequently, variable selection and class prediction analyses were conducted to choose a short list of blood-based protein biomarkers to predict AD. Two sets (primary and validation) of biomarkers were measured in plasma from fasting participants using a commercial assay (APOE4/Pan APOE ELISA; MBL Co, Ltd), as previously described. Total plasma (lithium heparin) metal iron levels were measured by induction-coupled plasma mass spectrometry. Seven metals were measured: chromium (isotopes 52 and 53; Cr), copper (isotope 65; Cu), iron (isotope 57; Fe), rubidium (isotope 85; Rb), selenium (isotope 78; Se), and zinc (isotope 66; Zn). All available data from a subset of the ADNI study cohort (HC, 58; AD, 112) measured for the RBM protein analyte panel and various clinical pathology measures were used for validation purposes. Information regarding biological preparation of ADNI samples and analysis of the RBM Human DiscoveryMAP panel can be found at the ADNI websites (see also the eAppendix; http://www.archneurol.com).

Figure 1. Statistical method mind-map. Defines commonly used terms for statistical analyses pathways 1 and 2, statistical methods sets 1 and 2, and model prediction approaches 1, 2, and 3. APOE indicates apolipoprotein E; LIMMA, linear models for microarray; SAM, significance analyses of microarray; and SVM, support vector machine.
RESULTS

BASELINE CHARACTERISTICS

Baseline sample characteristics of the AIBL and ADNI cohorts for demographic and clinical classifications are presented in Table 1. Comparisons were undertaken between cohorts with respect to HCs, AD cases, and a combined overall grouping. Significant distributional differences were found for age, educational level, APOE genotype, and Clinical Dementia Rating (CDR) score; no significant differences in the distributions of body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) and sex across the 2 cohorts were observed (Table 1). When the groups were stratified, the proportions of AD participants were very similar for both CDR and APOE genotype, whereas the proportions of HCs for the same demographic variables were significantly different (CDR, \( P = .0004 \); APOE genotype, \( P = .003 \)). On average, the Mini-Mental State Examination score was lower in AIBL AD participants than in ADNI AD participants, whereas HCs in both cohorts had the same Mini-Mental State Examination score. Comparing age between cohorts, the AIBL cohort had a higher proportion of younger (<70 years) HCs than did the ADNI cohort (35% vs 4%) and also had a higher proportion of older (≥80 years) participants with AD (68% vs 52%). Healthy controls from the AIBL cohort tended to have more years of education compared with those from the ADNI, and there was a higher proportion of HCs in the ADNI cohort who had a CDR score of 0.5.

In addition to the cohort comparisons presented in Table 1, BMI and educational levels were compared between the AD and HC groups (AIBL sample data). Data on educational level were collected using published standards15 (Table 1); however, for the purposes of these analyses, 3 groups were created (0-6, 7-8, and 9-12 years of education). Compared with HCs, the AD group was 3.7 times more likely to have fewer than 9 years of education (\( P < .0001 \)). Body mass index was categorized into 3 levels (≤25, 25-30, and >30). Healthy controls were 2.8 times as likely to have BMIs greater than 30 than were individuals with AD (\( P = .002 \)).
BIOMARKER DATA SET COMPARISONS

After data cleaning and imputation, characterization of the biomarker data sets from the AIBL and ADNI cohorts revealed that, of the multiplexed biomarkers assayed, 111 were suitable for analysis from the AIBL cohort and 136 were suitable from the ADNI cohort (remaining biomarkers had >10% missing values). Of these, 96 were common to both cohorts. In addition to these protein markers, 52 standard clinical pathology markers, 7 markers of metal ions, and circulating levels of Aβ1-40 and Aβ1-42 were measured in the AIBL cohort. Thirty-eight clinical pathology markers were available from the ADNI cohort, of which 22 matched those from AIBL.

Comparing protein values between HCs and AD patients, 21 biomarkers showed a significant fold change ($P < .0003$) (Table 2) from the AIBL cohort, but only 2 biomarkers from the ADNI cohort were altered at this level of significance ($P < .0003$). The eTable compares the top 21 biomarkers from the AIBL and ADNI cohorts from variable selections, according to fold change. Biomarkers among the top 21 from both the AIBL and ADNI cohorts included pancreatic polypeptide (PPY), tissue inhibitor of metalloproteinases 1, tumor necrosis factor receptor–like 2, and vascular cell adhesion molecule 1 (VCAM1). Analytes only available in the AIBL cohort that were significantly altered in the AD participants compared with HCs ($P < .0003$) included homocysteine, interleukin 10 (IL-10), IL-17, and zinc.

### BIOMARKER SELECTION IN THE AIBL COHORT

From a total of 174 biomarkers, 18 markers were selected in the AIBL cohort: 11 markers from the RBM array, 5 clinical pathology variables, 1 metal ion, and the commercial assay for APOE (Table 2). Of the 21 biomarkers that showed a significant fold change in AD patients compared with HCs, 6 biomarkers that were selected using the suites of variable selection methods did not reach significance once they were adjusted for age, sex, APOE genotype, and Bonferroni multiple comparisons (Table 2). The protein fold difference between AD patients and HCs was highest for insulin-like growth factor binding protein 2 (IGFBP2) (1.61-fold). Pancreatic polypeptide was the only other protein that was at least 1.5-fold greater in AD patients compared with HCs (1.54-fold).

Biomarkers were selected for prediction if they were chosen from all 4 statistical methods in set 1 (random forest, boosted trees, regression trees, and linear models for microarray), and were then validated using set 2 (best first, greedy stepwise, forward selection regression, and significance analyses of microarray) or recursive feature elimination–support vector machine. The number of biomarkers that were selected by these methods and that were common between the sets is illustrated in Figure 2. Biomarkers that were selected in at least 2 of 3 methods (21 biomarkers) were subject to statistical analysis pathway 2. Further statistical assessment of the 21 biomarkers (stepwise removal of biomarkers based on predictive accuracy) removed 3 biomarkers (tumor necrosis factor receptor–like 2, tissue inhibitor of metalloproteinases 1, and vascular endothelial growth factor), leaving a final panel of 18 biomarkers (biomarker set A; Table 2).

### DISEASE PREDICTIONS

Model predictions in the AIBL cohort (Figure 3A) for the demographic variables (age, sex, and APOE genotype) resulted in a sensitivity and specificity (SD) of 77% (3.0%) and an area under the receiver operating characteristic curve (AUC) of 84% (3.0%). Adding biomarker set A to age, sex, and APOE genotype improved the sensitivity and specificity to 85% (3.0%) and the AUC to 89% (3.0%). Reducing the number of biomarkers to 8 (cortisol, IGFBP2, PPY, IL-17, VCAM1, β2 microglobulin [B2M], epidermal growth factor receptor, and carcinoembryonic antigen; biomarker set B) reduced the sensitivity and specificity by only 2%. Adding covariates such as educational level and BMI increased the sensitivity and specificity by 0.9% in all models.

---

**Table 2. AIBL Biomarkers With Significantly Altered Levels Between AD Participants and Healthy Controls**

<table>
<thead>
<tr>
<th>AIBL Biomarker</th>
<th>Fold</th>
<th>P Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Insulin-like growth factor binding protein 2</td>
<td>1.61</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Pancreatic polypeptide</td>
<td>1.54</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Erythrocyte sedimentation rate</td>
<td>1.46</td>
<td>.002</td>
</tr>
<tr>
<td>B lymphocyte chemotaxant</td>
<td>1.45</td>
<td>.002</td>
</tr>
<tr>
<td>Carcinoembryonic antigen</td>
<td>1.40</td>
<td>.001</td>
</tr>
<tr>
<td>Cortisol</td>
<td>1.28</td>
<td>.0001</td>
</tr>
<tr>
<td>Tumor necrosis factor receptor-like 2</td>
<td>1.27</td>
<td>.0002</td>
</tr>
<tr>
<td>Homocysteine</td>
<td>1.23</td>
<td>.002</td>
</tr>
<tr>
<td>Angiopoietin 2</td>
<td>1.23</td>
<td>.003</td>
</tr>
<tr>
<td>Matrix metalloproteinase 9</td>
<td>1.19</td>
<td>.001</td>
</tr>
<tr>
<td>Vascular cell adhesion molecule 1</td>
<td>1.18</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Tissue inhibitor of metalloproteinases 1</td>
<td>1.18</td>
<td>.0003</td>
</tr>
<tr>
<td>Superoxide dismutase</td>
<td>1.16</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Alpha 1 antitrypsin</td>
<td>1.11</td>
<td>.0003</td>
</tr>
<tr>
<td>Interleukin 10</td>
<td>1.10</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Mean cell hemoglobin concentration</td>
<td>0.99</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Albumin</td>
<td>0.95</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Hemoglobin</td>
<td>0.95</td>
<td>.0003</td>
</tr>
<tr>
<td>Calcium</td>
<td>0.94</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Zinc (isotope 66)</td>
<td>0.91</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Interleukin 17</td>
<td>0.87</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>p5 microglobulin</td>
<td>1.24</td>
<td>.006</td>
</tr>
<tr>
<td>CD40</td>
<td>1.21</td>
<td>.040</td>
</tr>
<tr>
<td>Matrix metalloproteinase 2</td>
<td>1.13</td>
<td>.101</td>
</tr>
<tr>
<td>Macrophage inflammatory protein 1a</td>
<td>1.12</td>
<td>.006</td>
</tr>
<tr>
<td>Apolipoprotein E (commercial assay)</td>
<td>0.97</td>
<td>.042</td>
</tr>
<tr>
<td>Epidermal growth factor receptor</td>
<td>0.89</td>
<td>.012</td>
</tr>
</tbody>
</table>

Abbreviations: AD, Alzheimer disease; AIBL, Australian Imaging Biomarker and Lifestyle.  
A Biomarkers are ranked in order of fold overexpression and underexpression in patients with AD compared with healthy controls (HCs), calculated by dividing the raw unadjusted protein/clinical biomarker level in the AD group by the HC group.  
B For fold regulation, a value less than 1 indicates downregulated in AD; a value greater than 1, upregulated in AD.  
C P values are shown from a generalized linear model, adjusted for age, sex, and APOE genotype. Rank does not indicate the level of importance, with tags attached to specific biomarkers denoting the importance of proteins within the identified biomarker signatures.  
D Biomarkers contained within biomarker set A and set B.  
E Biomarker contained within biomarker set A.
In this study, we identified an 18-biomarker signature panel for the diagnosis of AD in the AIBL cohort and validated them in the ADNI population. We showed that including demographic and clinical information (educational level and BMI) together with these blood-based biomarkers and adjusting for age, sex, and APOE genotype strengthens the accuracy of disease prediction.

The validation analyses using both cohorts demonstrated the strength of the chosen biomarkers. Reducing the number of biomarkers in the signature panel to 8 (B2M, carinoembryonic antigen, cortisol, epidermal growth factor receptor, IGFBP2, IL-17, PPY, and VCAM1) using the AIBL data reduced the accuracy of the prediction by only 2%; the same reduction using the ADNI data as the validation set increased the prediction accuracy over using the full set of 18 biomarkers. Reducing the signature of biomarkers in the diagnostic panel increases its usefulness, initially within the clinical setting and after further validation for population screening. We acknowledge that the differences between the 2 cohorts, such as the reduced number of samples, the ratio of AD patients to HCs, and the differences in age, educational status, CDR score, and APOE ε4 allele status, may all play a role in validation accuracy.

From all biomarkers identified, cortisol, IGFBP2, and PPY were the ones most frequently chosen. The elevation of cortisol in AD participants presented herein and its presence as a part of the biomarker signature are in concordance with previously published studies. Moreover, Lupien et al found that prolonged exposure to the adrenal glucocorticoid aligns with reduced hippocampal volume and hippocampus-related memory tasks. Porter and Landfield proposed multiple hypotheses regarding the aging effects of prolonged exposure to adrenal hormones and suggested that the interaction between aging, stress, and glucocorticoids increases vulnerability and cognitive impairment. The effects of chronic glucocorticoid exposure and hippocampal volume in animal models have been summarized by Tata and Anderson. Recently, McAuley et al showed, from an in silico model, a potential 30% to 40% decrease in hippocampal activity with long-term elevated levels of cortisol. They showed that a biological intervention to such a system might reduce the decrease of hippocampal activation by 22%. However, subsequent reports have shown that cortisol is both a putative biomarker, as part of a large panel, for the classification of patients with schizophrenia and is elevated in that population. These data, together with the results from the present study, indicate that further research validating cortisol levels across different neurologic diseases is required to determine its specificity.

In addition to the present study on blood-based biomarkers, IGFBP2 was found to be higher in the CSF of individuals with AD in 2 other studies. The second of these studies reported a significant increase in IGFBP2 in both CSF and serum. A more recent study using the same multiplex panel as in the present study, failed to detect a significant change in IGFBP2 levels in the CSF of patients with AD; however, IGFBP2 was correlated with the levels of CSF tau. To the best of our knowledge, the study of Craig-Schapiro and colleagues has been the only other one to find PPY and IL-17 significantly altered in the CSF of individuals with AD compared with the CSF of HCs.

Davidsson et al identified B2M along with APOE and others as significantly altered proteins in the CSF of participants with AD compared with healthy controls. Our study showed increased B2M levels among patients with AD compared with controls; B2M is a small component of the major histocompatibility complex class I heavy chain and is involved with membrane turnover and elimination. Furthermore, because there is evidence that B2M is increased in other diseases in which the immune response is elevated, research has suggested that it is a marker of the immunologic state in vivo.
To our knowledge, this study is the first to show a relationship between epidermal growth factor receptor and AD. Zhang et al. found that the Alzheimer Aβ precursor protein intracellular domain (released as a result of γ secretase cleavage) mediated the transcriptional regulation of epidermal growth factor receptor. It is thus possible that in the presence of abnormal Aβ amyloid precursor protein there may be a corresponding increase in the transcription of epidermal growth factor receptor and an increase in serum levels of EGFR. Further research focused on the gene expression of EGFR is currently under way to validate this hypothesis.

Carcinoembryonic antigen has not previously been found to be associated with AD. Carcinoembryonic antigen, like VCAM1, is a cell adhesion molecule and belongs to a large family of immunoglobulins. O’Bryant et al. suggested an inflammatory endophenotype of AD from the large proportion of inflammatory markers identified in their study. Our finding of markers such as carcinoembryonic antigen, VCAM1, IL-17, macrophage inflammatory protein 1α, and B2M is related to immune system functionality and supports the hypothesis that there is an inflammatory endophenotype in AD.

Our results agree with those of O’Bryant and colleagues in that there is an abundance of inflammatory markers in our findings; however, this may be the result of the high proportion of inflammatory markers in the RBM panel used in both studies by O’Bryant et al. and in our study. Certainly, newer RBM biomarker panels have more proteins from multiple pathways represented.

We also report considerable overlap with biomarkers identified by Soares and colleagues, in particular with respect to univariate analyses, for which increased levels of N-terminal pro–brain natriuretic peptide (NT-proBNP), eotaxin 3, matrix metalloproteinase 1, PYY, and tenascin C and decreased levels of IgM and APOE were reported. Furthermore, multivariate analyses identified that APOE and NT-proBNP were of particular importance in contributing to the increased accuracy of the classification of AD. Although we also identified decreased APOE (in biomarker set A), NT-proBNP was not included in the multiplexed panel used in this study; however, its identification in CSF by Craig-Schapiro and colleagues provides evidence of its probable importance in AD. Likewise, there is growing support for the importance of APOE protein levels as a biomarker for disease.

We performed rigorous statistical analyses of a large biomarker set from the AIBL study and validated these results using comparable biomarker data from the ADNI study. Using a suite of statistical methods, we found the markers cortisol, PYY, IGFBP2, IL-17, VCAM1, B2M, EGFR, and carcinoembryonic antigen to be part of a blood-based signature to determine AD. We stress the importance that the biomarkers identified are blood based. Such an improvement in diagnostic predictive power over the base model of age, sex, and APOE ε4 allele has identified the combinatorial strength of blood-based markers, in which prior benchmarks are derived from highly sensitive but invasive CSF testing. Selection of these biomarkers after such thorough statistical analysis and validation of these markers using a second cohort provide strong evidence of their importance in AD pathogenesis and, in turn, AD diagnosis. Whether their accuracy can be improved in combination with biomarkers identified in recent studies needs to be determined.

Figure 3. Receiver operating characteristic (ROC) curves for comparison of biomarker set performance in the Australian Imaging Biomarker and Lifestyle study (AIBL) and the Alzheimer Disease Neuroimaging Initiative (ADNI) data sets. A. The ROC curves represent the area under the ROC curve (AUC) as tested using the AIBL data only. The AUC comparison in the AIBL data set used (1) age, sex, and presence of the apolipoprotein E (APOE) ε4 allele (red line); (2) age, sex, APOE ε4 allele, and the 18-variable biomarker set A (green line); and (3) age, sex, APOE ε4 allele, and the reduced B-variable biomarker set B (blue line). B. The ROC curves represent a comparison between class predictions when using only AIBL protein biomarker data or when using ADNI protein biomarkers as the validatory data set. The AUC comparison of 4 different prediction models used (1) the AIBL data set: age, sex, presence of the APOE ε4 allele, and biomarker set A (red line; equivalent of green line in A); (2) cross validation of the AIBL data set using markers available from both cohorts, that is, age, sex, presence of the APOE ε4 allele, and biomarker set A minus interleukin 17 (IL-17), Zn, and homocysteine (blue line); (3) the ADNI data set: age, sex, presence of the APOE ε4 allele, and biomarker set A minus IL-17, Zn, and homocysteine (green line); and (4) the ADNI data set: age, sex, APOE ε4 allele, and biomarker set B minus IL-17 (yellow line).
Accepted for Publication: April 13, 2012.
Published Online: July 16, 2012. doi:10.1001/archneurol.2012.1282

Author Affiliations: The Australian E-Health Research Centre, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia (Dr Doecke); The Commonwealth Scientific and Industrial Research Organisation (CSIRO) Preventative Health Flagship, CSIRO Materials Science and Engineering (CMSE), Parkville, Victoria, Australia (Drs Doecke, Wilson, Head, Macaulay, and Szoeko); CSIRO Mathematics and Information Sciences, Macquarie University, Australia (Drs Doecke and Wilson); Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, Joondalup, Western Australia, Australia (Drs Laws, Gupta, and Martins; Mss Brown and Taddei; and Messrs Mondal, De Ruyck, Rodrigues, and Taddei); Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, Western Australia, Australia (Drs Laws, Gupta, and Martins; Mss Brown and Taddei; and Messrs Mondal, De Ruyck, Rodrigues, and Taddei); Mental Health Research Institute, Parkville, Victoria, Australia (Drs Faux, Bush, Rembach, and Masters; Mss Pertile and Rumble; and Messrs Fowler and Trounson); University of Melbourne, Parkville, Australia (Drs Faux, Bush, and Masters); CSIRO Mathematics and Information Sciences, Western Australia, Australia (Dr Burnham); School of Computer and Security Science, Edith Cowan University, Mount Lawley, Western Australia, Australia (Dr Lam); Victorian Research Laboratory, National Information and Communications Technology Australia (NICTA) (Dr Bedo); Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, St Vincent's Aged Psychiatry Service, St George's Hospital Campus, Victoria, Australia (Drs Ellis and Ames); Austin Health, Heidelberg, Victoria, Australia (Dr Rowe); National Ageing Research Institute, Parkville, Victoria, Australia (Drs Szoeko, Ames, and Masters); and Centre for Neuroscience, University of Melbourne, Parkville, Australia (Dr Masters).

Correspondence: Ralph N. Martins, PhD, Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, 270 Joondalup Dr, Joondalup, WA 6027, Australia (r.martins@ecu.edu.au).


Funding/Support: Data collection and sharing for this project was funded by the ADNI (National Institutes of Health [NIH] grant U01 AG024904). The ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Abbott Laboratories; Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Amorfix Life Sciences Ltd; AstraZeneca; Bayer HealthCare; Bioclinica, Inc; Biogen Idec Inc; Bristol-Myers Squibb Company; Eisai Inc; Elan Pharmaceuticals Inc; Eli Lilly and Company; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc; GE Healthcare; Immogenetics, NV; Janssen Alzheimer Immunotherapy Research & Development, LLC; Johnson & Johnson Pharmaceutical Research & Development LLC; Medpace, Inc; Merck & Co, Inc; Meso Scale Diagnostics, LLC; Novartis Pharmaceuticals Corporation; Pfizer Inc; Servier; Synarc Inc; and Takeda Pharmaceutical Company. The Canadian Institutes of Health Research provides funds to support ADNI clinical sites in Canada. Private sector contributions are facilitated by the Foundation for the NIH (http://www.fnih.org). The grantee organization is the Northern California Institute for Research and Education, and the study is coordinated by the Alzheimer's Disease Cooperative Study at the University of California, San Diego. The ADNI data are disseminated by the Laboratory for Neuro Imaging at the University of California, Los Angeles. This research was also supported by NIH grants P30 AG010129 and K01 AG030514. Core funding for the study was provided by CSIRO and the Science and Industry Endowment Fund (SIEF) (http://www.sief.org.au), which was supplemented by in-kind contributions from the study partners (see http://www.aibl.csiro.au/). The AIBL investigators thank Dr Head of CSIRO for initiating and facilitating the AIBL collaboration. The study also received support from the National Health and Medical Research Council (NHMRC) via the Dementia Collaborative Research Centres program (DRCR2). Pfizer International, AstraZeneca, and GE Healthcare have contributed financial support to further the AIBL research program. The McCusker Foundation has contributed financial and in-kind support to AIBL. Dr Faux is supported by an NHMRC training fellowship. Drs Laws and Gupta were supported through the Office of Research and Innovation at Edith Cowan University. Dr Szoeko is partially supported by a research fellowship funded by Alzheimer's Australia. Alzheimer's Australia (Victoria and Western Australia) assisted with promotion of the study and the screening of telephone calls from volunteers.

Additional Information: Data used in preparation of this article were obtained from the ADNI database (http://www.adni.loni.ucla.edu). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report.
REFERENCES